Abstract 1697
Background
The patients’ (pts) illness perception is based on dimensions of cognitive understanding and emotional representations of disease and its symptoms. Previous studies reported that illness perceptions influence quality of life (QoL) and mood.
Methods
212 pts with metastatic breast cancer, under treatment, were evaluated by Illness Perception Questionnaire Brief version (IPQ-B), EORTC Quality of Life Questionnaire (QLQ-30) and Hospital Anxiety and Depression Scale (HADS). IPQ-B higher scores indicate a negative perception. EORTC QLQ-30 higher scores indicate better functioning/QoL or worse symptom severity. Higher HADS indicate higher anxiety/depression (AD) levels. Variables were studied using Pearls correlation (Sig 0.01) and T test. Primary endpoint was evaluation of illness perception. Secondary endpoints were assessment of pts characteristics, QoL, AD and its associations with illness perception.
Results
Median age was 64 years (y) and 99.5% (211 pts) were women. Median IPQ-B score was 18/32. All patients reported that their breast cancer is incurable. Perception of disease consequences was more negative in pts younger than 70y versus 70y or older (2.7 vs 2.3, p = 0.039). Preoccupation and perception of control with treatment were higher in younger pts (3.4 vs 2.9, p = 0.004; 3.6 vs 3.3, p = 0.03; respectively). Pts under chemotherapy and/or anti-HER2 therapy shown a greater impact of disease consequences, than pts under endocrine therapy and/or other target therapies (2.6 vs 2.3, p = 0.039). The mean overall QoL was 54.6/100 (± 23.0). Physical, cognitive, social and emotional functioning mean scores were respectively 60.3, 69.1, 69.3 and 60.3/100; all lower than EORTC ref. values (p < 0.01). Social functioning and IPQ-B shown a moderate negative correlation (r = - 0.507). The mean HADS score was 16.9/42 (± 7.8), reflecting the AD subscales (respectively, 9.1/21; 7.8/21). The overall illness perception and HADS shown a moderate positive association (r = 0.62). Anxiety and the emotional dimension of IPQ-B had a moderate positive correlation (r = 0.598).
Conclusions
Integrating in clinical practice the relation between illness perceptions, QoL and AD, may improve disease’s coping mechanisms and functional capacity (physical, emotional, social).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2107 - Role of Individualized Intervention(s) on Quality of Life (QOL) and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women with Early-Stage Breast Cancer (BC): MyChoice Study
Presenter: Shahid Ahmed
Session: Poster Display session 2
Resources:
Abstract
5812 - Correlation between the density of tumor-infiltrating lymphocytes, immune cell subsets in tumor stroma and response to systemic therapy in breast cancer
Presenter: Cvetka Grasic Kuhar
Session: Poster Display session 2
Resources:
Abstract
4734 - BRCA1/2 Testing in HER2- Advanced Breast Cancer (ABC): Results from the European Component of a Multi-Country Real World Study
Presenter: Michael Patrick Lux
Session: Poster Display session 2
Resources:
Abstract
1686 - In vitro and in vivo rescue of resistance to BET inhibitors by targeting PLK1 in triple negative breast cancer.
Presenter: Cristina Nieto-jiménez
Session: Poster Display session 2
Resources:
Abstract
5020 - Neoadjuvant endocrine therapy in combination with melatonin and metformin in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
5082 - Melatonin and metformin in neoadjuvant chemotherapy in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
2642 - Patient-tailored tamoxifen dosing based on an increased quantitative understanding of its complex pharmacokinetics: A novel integrative modelling approach
Presenter: Anna Mueller-Schoell
Session: Poster Display session 2
Resources:
Abstract
2461 - Lack of benefit of neoadjuvant pertuzumab in high risk HER2 positive breast cancer. A retrospective case-control study of 355 cases with biomarker analysis.
Presenter: Manuela Tiako Meyo
Session: Poster Display session 2
Resources:
Abstract
4776 - Targeting CDCA3 to improve chemotherapy response in triple-negative breast cancer patients
Presenter: Kenneth O'Byrne
Session: Poster Display session 2
Resources:
Abstract
1674 - Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Presenter: María Del Mar Noblejas López
Session: Poster Display session 2
Resources:
Abstract